Abstract
Cold agglutinin syndrome is one of the rare immune-related adverse events of nivolumab.
Rituximab should be considered for treatment of nivolumab-induced cold agglutinin syndrome.
MeSH terms
-
Aged, 80 and over
-
Anemia, Hemolytic, Autoimmune / chemically induced*
-
Anemia, Hemolytic, Autoimmune / drug therapy*
-
Anemia, Hemolytic, Autoimmune / pathology*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology
-
Carboplatin / administration & dosage
-
Carboplatin / adverse effects
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Female
-
Gemcitabine
-
Humans
-
Lymphoma, B-Cell, Marginal Zone / drug therapy
-
Lymphoma, B-Cell, Marginal Zone / pathology
-
Neoplasms, Second Primary / chemically induced
-
Neoplasms, Second Primary / drug therapy
-
Neoplasms, Second Primary / pathology
-
Nivolumab / administration & dosage
-
Nivolumab / adverse effects*
-
Rituximab / administration & dosage*
-
Syndrome
Substances
-
Deoxycytidine
-
Nivolumab
-
Rituximab
-
Carboplatin
-
Gemcitabine